Baystreet.ca News Commentary — The global precision oncology market is on pace to reach $303 billion in 2035[1], a figure that reflects more than steady growth, signaling a structural ...

Pulse Biosciences recently reported first patient treatments in a multi-center, first-in-human feasibility study of its FDA-cleared nPulse Vybrance Percutaneous Electrode System using nanosecond ...

Some studies suggest that people who are prone to thyroid carcinoma showed low levels of vitamin D compared to people who were not with cancer. To know what the findings of the study are, read on.

Plus, who should be on alert.

Study finds up to 94% of papillary thyroid cancers in the past three decades were overdiagnosed, with stable mortality rates, ...

After undergoing surgery to remove an overactive thyroid in 2014, games designer and publisher Xeo Lye had jokingly asked his doctor how long he could survive without thyroid hormone replacement pills ...

Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse Vybrance system.

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse ...

It can be surprising to learn that lung cancer can develop in people who have never smoked. In fact, up to 20% of lung cancers occur in people without a history of smoking. While smoking remains the ...